文献速递皮肤肿瘤

发疹性鳞状细胞异型增生(ESA)的定义及病灶内5-氟尿嘧啶治疗成功管理

Eruptive squamous atypia (also known as eruptive keratoacanthoma): Definition of the disease entity and successful management via intralesional 5-fluorouracil.
PubMed 文献 · J Am Acad Dermatol · 2019-05-15

本研究回顾性定义发疹性鳞状细胞异型增生(ESA,又称发疹性角化棘皮瘤)并评估病灶内5-氟尿嘧啶(IL 5-FU)疗效。30例患者共136处ESA病灶,20例(67%)经IL 5-FU单药治疗消退,无病灶需手术切除,切除手术次数显著减少(P = .006),仅色素沉着为不良反应。

要点

  • ESA是特发性非典型角质形成细胞增殖,常被误诊为癌而手术,手术可诱发同形反应。
  • IL 5-FU单药可使67%患者ESA消退,无病灶需手术切除。
  • IL 5-FU治疗后12个月需手术切除次数较前12个月显著减少(P = .006)。

核心结论

  • 在密切临床监测下,病灶内5-氟尿嘧啶可成功治疗发疹性鳞状细胞异型增生(ESA)。

研究设计与样本

  • 回顾性队列研究,纳入2008年1月至2016年12月于三级学术中心接受IL 5-FU治疗的ESA患者,ESA为自发或近期手术瘢痕内出现。
  • 共30例患者、136处ESA病灶。

主要发现

  • 20例(67%)患者经IL 5-FU单药治疗ESA消退。
  • 10例(33%)需额外治疗(外用5-FU、类固醇、冷冻或阿维A)。
  • 无IL 5-FU治疗的ESA病灶需手术切除。
  • 切除手术次数显著减少(P = .006),27例(90%)在IL 5-FU治疗开始后12个月较前12个月需更少切除。
  • 色素沉着是唯一不良事件。

临床怎么用

  • ESA应避免误诊为癌而直接手术切除,因手术可能诱发同形反应。
  • 在密切临床监测下,可选用病灶内5-FU治疗ESA,以减少手术切除需求。

局限性

  • 回顾性分析。
  • 单中心数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Eruptive squamous atypia (ESA), which is an idiopathic, sometimes koebnerizing, proliferation of atypical but well-differentiated keratinocytes (also termed eruptive keratoacanthoma), is often misdiagnosed as cancer and managed by excisional surgery, provoking further koebnerization. A clear definition of this phenomenon and treatment outcome data are lacking. OBJECTIVE: To define ESA and evaluate efficacy of intralesional (IL) 5-fluorouracil (5-FU) treatment. METHODS: A retrospective cohort study examined patients with ESA that arose spontaneously or within a recent surgical scar and was treated with IL 5-FU at a tertiary academic center between January 2008 and December 2016. Complete clearance, partial clearance, and number of surgical excisions performed were tabulated. RESULTS: Of 30 patients with 136 ESA lesions, 20 (67%) had resolution of ESA with IL 5-FU monotherapy. In all, 10 patients (33%) required additional therapy (topical 5-FU, steroids, cryotherapy, or acitretin). No IL 5-FU-treated ESA lesions required surgical excision. The number of excisional procedures decreased significantly (P = .006), with 27 patients (90%) needing fewer excisions 12 months after versus 12 months before initiation of IL 5-FU therapy. Dyspigmentation was the only adverse event. LIMITATIONS: Limitations include retrospective analysis and use of data from a single institution. CONCLUSION: With close clinical monitoring, IL 5-FU can be used to successfully treat ESA.

来源:J Am Acad Dermatol,查看原文。版权归原作者所有。

引用

  1. Que SKT, Compton LA, Schmults CD, et al. Eruptive squamous atypia (also known as eruptive keratoacanthoma): Definition of the disease entity and successful management via intralesional 5-fluorouracil. J Am Acad Dermatol. 2019. PMID: 31103317. doi:10.1016/j.jaad.2018.10.014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。